Source: Health Canada shortage reports · Updated Jul 29, 2026
A shortage of Alirocumab is anticipated but not yet confirmed. 1 product(s) have anticipated-shortage reports on file with Health Canada.
A PCSK9 inhibitor used to lower high cholesterol.
Products affected
0 / 3
Reports on file
15
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Anticipated
PRALUENT
300MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02547732
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Feb 6, 2026
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Jun 5, 2024 · Manufacturing Delay
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Dec 22, 2023
Resolved
PRALUENT
75MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453819 · ended Dec 22, 2023
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended May 31, 2023 · Manufacturing delay.
Resolved
PRALUENT
75MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453819 · ended Feb 2, 2023
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Jan 26, 2023
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended Dec 22, 2022 · Demand increase for the drug.
Resolved
PRALUENT
75MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453819 · ended Nov 8, 2021
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended May 3, 2021 · A manufacturing delay may create a short term shortage. Supplies are expected by early May, shortage should be avoided as allocation will be put in place.
Resolved
PRALUENT
150MG · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02453835 · ended May 9, 2019
Showing 12 of 15 reports. All reports are on file with Health Canada.
What's happening
A manufacturer has told Health Canada it expects supply of Alirocumab to fall short of demand. Anticipated shortages sometimes resolve without patients noticing; this page updates as soon as the status changes.
Alirocumab is classified under “LIPID MODIFYING AGENTS, PLAIN” (ATC C10AX).
Recent changes
Jul 29, 2026
New report filed
Common questions
What is Alirocumab used for?
A PCSK9 inhibitor used to lower high cholesterol.
When will Alirocumab be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Alirocumab in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.